The history of Viagra presents a interesting case for stakeholders in the medicinal sector. While initially a phenomenal success, generating huge profits, the patent lapse and the subsequent entry of generic versions have considerably changed earnings. This poses questions about the long-term viability of analogous medication projects and suggests